Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Just In
Assassination plot: Three Iranians charged in plot to kill Donald Trump
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silexion Therapeutics Corp - Ordinary Shares
(NQ:
SLXN
)
0.2624
-0.0148 (-5.34%)
Streaming Delayed Price
Updated: 3:59 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Silexion Therapeutics Corp - Ordinary Shares
Silexion Therapeutics Unveils Promising Preclinical Data for SIL-204 Just Days After New LODER Data: Advancing the Fight Against Pancreatic Cancer
October 01, 2024
Via
AB Newswire
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
October 01, 2024
From
Silexion Therapeutics Corp.
Via
Business Wire
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment
September 24, 2024
Via
AB Newswire
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
September 24, 2024
From
Silexion Therapeutics
Via
Business Wire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Via
AB Newswire
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
September 09, 2024
From
PESG Research
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.